Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) closed at $383.12 in the last session, down -1.03% from day before closing price of $387.11. In other words, the price has decreased by -$1.03 from its previous closing price. On the day, 3.39 million shares were traded. VRTX stock price reached its highest trading level at $389.46 during the session, while it also had its lowest trading level at $382.6.
Ratios:
We take a closer look at VRTX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.07. For the most recent quarter (mrq), Quick Ratio is recorded 2.16 and its Current Ratio is at 2.52. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
On August 06, 2025, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $460.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 27 ’25 when Bhatia Sangeeta N. sold 266 shares for $386.69 per share. The transaction valued at 102,860 led to the insider holds 4,565 shares of the business.
Bhatia Sangeeta N. bought 266 shares of VRTX for $102,860 on Aug 27 ’25. On Aug 06 ’25, another insider, Kewalramani Reshma, who serves as the CEO & President of the company, bought 10,000 shares for $389.58 each. As a result, the insider paid 3,895,768 and bolstered with 115,968 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRTX now has a Market Capitalization of 98228387840 and an Enterprise Value of 93372989440. As of this moment, Vertex’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.38, and their Forward P/E ratio for the next fiscal year is 18.60. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.62 while its Price-to-Book (P/B) ratio in mrq is 5.72. Its current Enterprise Value per Revenue stands at 8.177 whereas that against EBITDA is 19.447.
Stock Price History:
The Beta on a monthly basis for VRTX is 0.43, which has changed by -0.16713041 over the last 52 weeks, in comparison to a change of 0.1653893 over the same period for the S&P500. Over the past 52 weeks, VRTX has reached a high of $519.88, while it has fallen to a 52-week low of $362.50. The 50-Day Moving Average of the stock is -7.90%, while the 200-Day Moving Average is calculated to be -14.72%.
Shares Statistics:
According to the various share statistics, VRTX traded on average about 1.69M shares per day over the past 3-months and 1665140 shares per day over the past 10 days. A total of 256.29M shares are outstanding, with a floating share count of 255.58M. Insiders hold about 0.32% of the company’s shares, while institutions hold 96.24% stake in the company. Shares short for VRTX as of 1756425600 were 3639292 with a Short Ratio of 2.15, compared to 1753920000 on 4362540. Therefore, it implies a Short% of Shares Outstanding of 3639292 and a Short% of Float of 1.6.
Earnings Estimates
As of right now, 22.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $4.93, with high estimates of $5.29 and low estimates of $4.54.
Analysts are recommending an EPS of between $18.83 and $16.61 for the fiscal current year, implying an average EPS of $18.03. EPS for the following year is $20.21, with 23.0 analysts recommending between $23.6 and $18.31.
Revenue Estimates
According to 26 analysts,. The current quarter’s revenue is expected to be $3.05B. It ranges from a high estimate of $3.14B to a low estimate of $2.94B. As of. The current estimate, Vertex Pharmaceuticals, Inc’s year-ago sales were $2.77BFor the next quarter, 26 analysts are estimating revenue of $3.21B. There is a high estimate of $3.29B for the next quarter, whereas the lowest estimate is $3.1B.
A total of 30 analysts have provided revenue estimates for VRTX’s current fiscal year. The highest revenue estimate was $12.13B, while the lowest revenue estimate was $11.89B, resulting in an average revenue estimate of $11.99B. In the same quarter a year ago, actual revenue was $11.02BBased on 28 analysts’ estimates, the company’s revenue will be $13.22B in the next fiscal year. The high estimate is $15.35B and the low estimate is $11.94B.
